Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.85 |
| ▸ | MTOR | P42345 | 19/20 | 0.85 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.85 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.85 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.85 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.85 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.85 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.70 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1430208 | 0.98 | PIK3CA (0.87) | PIK3CAMTORPIK3CGPIK3CBPIK3CD | |
| SCHEMBL1431313 | 0.97 | PIK3CA (0.83) | PIK3CAMTORPIK3CGPIK3CBPIK3CD | |
| SCHEMBL4457772 | 0.96 | PIK3CA (0.79) | PIK3CAMTORPIK3CGPIK3CBPIK3CD | |
| SCHEMBL4471314 | 0.96 | PIK3CA (0.79) | PIK3CAMTORPIK3CGPIK3CBPIK3CD | |
| Gedatolisib SCHEMBL20765097 | 0.93 | MTOR (1.00) | PIK3CAMTORPIK3CGPIK3CBPIK3CD | |
| Gedatolisib SCHEMBL32393 | 0.93 | MTOR (1.00) | PIK3CAMTORPIK3CGPIK3CBPIK3CD | |
| SCHEMBL1431233 | 0.92 | PIK3CA (0.82) | PIK3CAMTORPIK3CGPIK3CBPIK3CD | |
| SCHEMBL1430506 | 0.90 | PIK3CA (0.84) | PIK3CAMTORPIK3CGPIK3CBPIK3CD | |
| SCHEMBL4467515 | 0.90 | PIK3CA (0.77) | PIK3CAMTORPIK3CGPIK3CBPIK3CD | |
| SCHEMBL32727 | 0.90 | MTOR (0.95) | PIK3CAMTORPIK3CGPIK3CBPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090304692-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-12-10 | — | — | US | claimed |
| EP-3216793-B1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3216793-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | Wyeth LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2294072-B1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20090304692-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304692-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | MTOR, PIK3CA, PIK3R3 | PIK3CA 2/4885MTOR 1/4885PIK3CG 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.